Apalutamide, a drug belonging to the androgen receptor inhibitor class, has become a cornerstone therapy for prostate cancer. But researchers aren't stopping there. Clinical trials are actively exploring apalutamide's potential in new and exciting ways. https://www.qingmupharm.com/apalutamide-a-second-generation-nsaa-for-non-metastatic-castration-resistant-prostate-cancer